Stock Movers Novo Nordisk Rallies, Johnson & Johnson Slides, ServiceNow Falls
Dec 23, 2025
Nora Melinda, a Bloomberg Television markets correspondent, shares her insights on major stock movements. Novo Nordisk celebrates its approval for an oral version of the obesity drug Wegovy, leading to a significant stock rally. On the downside, Johnson & Johnson faces a hefty $1.56 billion verdict related to talc litigation, impacting its shares. Meanwhile, ServiceNow announces its largest acquisition yet, buying cybersecurity startup Armis for $7.75 billion, though the market reacts cautiously.
AI Snips
Chapters
Transcript
Episode notes
Oral Pill Boosts Novo Nordisk Outlook
- Novo Nordisk's oral pill approval in the U.S. marks a crucial defensive move against Eli Lilly in obesity treatment.
- Shares jumped as much as 11% signaling investor relief after a 41% year-to-date decline for NVO.
Talc Verdict Keeps J&J Under Pressure
- A $1.56 billion verdict against Johnson & Johnson highlights ongoing legal risks tied to talc-based baby powder.
- The ruling contributed to a share decline as litigation continues to pressure JNJ stock.
ServiceNow Makes Biggest Cyber Acquisition
- ServiceNow's acquisition of Armis for $7.75 billion is its largest deal and reflects growing consolidation in cybersecurity.
- The transaction added to recent share weakness as investors digest the funding plan and strategic fit.